Document is current

Article History

Received: 5 July 2023

Accepted: 6 December 2023

First Online: 2 February 2024

Declarations

:

: Peter C. Black is a member of an advisory board or equivalent with a commercial organization: AbbVie, AstraZeneca, Astellas, Bayer, BMS, EMD-Serono, Ferring, Fergene, Janssen, Merck, miR Scientific, Nonagen, NanOlogy, Pfizer, Photocure, Prokarium, Protara Therapeutics, QED Bioscience, Roche, Sanofi, Sesen Bio, STIMIT, TerSera, Tolmar, Urogen, and Verity; is a member of a Speaker’s bureau: Janssen, Minogue, Ferring, TerSera, and Pfizer; has received a grant(s) or an honorarium from a commercial organization: iProgen; is currently participating in or has participated in a clinical trial within the past 2 years: Genentech, Janssen, BMS, AstraZeneca, Therelase, Pacific Edge, and Pfizer; and shares a patent with: Veracyte. He has no other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity. Bernhard J. Eigl has received honoraria from: BMS, Janssen, EMD Serono, Seagen, Gilead; and has received honoraria and research funding from: Pfizer.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.